Please login to the form below

Not currently logged in
Email:
Password:

BMS boosts immuno-oncology with $2.3bn IFM buy

Boston-based group will operate as a subsidiary of BMS

BMSBristol-Myers Squibb is paying a sizeable $300m upfront for IFM Therapeutics, getting its hands on two cancer programmes that will flesh out its cancer immunotherapy portfolio.

The privately-held biotech is working on drugs that stimulate STING and NLRP3 - two drug targets that IFM maintains play a key role in the immunological response to cancer, and such is BMS' enthusiasm for them that the big pharma is prepared to pay $1bn apiece in milestones if a candidate from each programme makes it through to market and meets sales expectations.

Additional milestones could also be payable if other drugs from IFM's stable advance through development, it said.

While still in preclinical development, the two programmes complement BMS' existing immuno-oncology, currently headed by marketed checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab).

The big pharma has steadily added to its portfolio with a stream of candidates targeting molecules such as CD137 (urelumab), IDO (BMS-986205), and LAG-3 (BMS-986016) - all in phase II testing - which it hopes will work alongside its marketed drugs in new cocktails that will enhance tumour responses.

The company is not averse to paying princely sums for those assets as it tries to keep ahead of its rivals in the immuno-oncology sector, estimated to be worth tens of billions of dollars in the coming years.  It paid $1.25bn - including $800m upfront - for IDO specialist Flexus in 2015 for example.

"IFM's STING agonist programme includes a lead asset that accelerates the company's efforts against this target, while the NLRP3 agonist program includes a potential first-in-class pipeline candidate," said BMS in a statement.

Adding the new candidates "broadens our ability to investigate additional pathways across the immune system", said BMS' chief scientific officer Thomas Lynch.

Boston-based IFM will continue to function very much as it does today under co-founder and chief executive Gary Glick, maintaining its current personnel and premises but operating as a subsidiary of BMS.

It will also continue to work on another project outside of cancer - focused on NLRP3 antagonists for inflammatory diseases and fibrosis - and BMS has first refusal rights to that programme.

Article by
Phil Taylor

4th August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

03_analytical_lowres.jpg
How to choose your digital channels
Like many other areas of marketing, pharma digital communication is subject to fashion. A new technology arrives, people naturally get excited. Meanwhile, established communication technologies receive less focus (even if...
Internships: Growing the pool of recruitable talent, or cheap labour?
Porterhouse Medical discusses the pros and cons of running internship programmes....
How to create a multi-channel marketing strategy and plan
You know what it is and why you need one, now find out how to create a successful pharma multi-channel marketing strategy and plan...

Infographics